188 related articles for article (PubMed ID: 31235628)
1. Mutations in
Romano KP; Warrier T; Poulsen BE; Nguyen PH; Loftis AR; Saebi A; Pentelute BL; Hung DT
Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31235628
[No Abstract] [Full Text] [Related]
2. PmrB mutations promote polymyxin resistance of Pseudomonas aeruginosa isolated from colistin-treated cystic fibrosis patients.
Moskowitz SM; Brannon MK; Dasgupta N; Pier M; Sgambati N; Miller AK; Selgrade SE; Miller SI; Denton M; Conway SP; Johansen HK; Høiby N
Antimicrob Agents Chemother; 2012 Feb; 56(2):1019-30. PubMed ID: 22106224
[TBL] [Abstract][Full Text] [Related]
3. Colistin kills bacteria by targeting lipopolysaccharide in the cytoplasmic membrane.
Sabnis A; Hagart KL; Klöckner A; Becce M; Evans LE; Furniss RCD; Mavridou DA; Murphy R; Stevens MM; Davies JC; Larrouy-Maumus GJ; Clarke TB; Edwards AM
Elife; 2021 Apr; 10():. PubMed ID: 33821795
[TBL] [Abstract][Full Text] [Related]
4. The Efflux Pump MexXY/OprM Contributes to the Tolerance and Acquired Resistance of Pseudomonas aeruginosa to Colistin.
Puja H; Bolard A; Noguès A; Plésiat P; Jeannot K
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964794
[TBL] [Abstract][Full Text] [Related]
5. Molecular analysis of PmrA and PmrB genes in colistin-resistant Pseudomonas aeruginosa strains via PCR method.
Heidari L; Sepahvand S; Darvishi M; Jafari R
Pak J Pharm Sci; 2019 May; 32(3 (Supplementary)):1175-1177. PubMed ID: 31303587
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and molecular characterization of colistin resistance in Pseudomonas aeruginosa isolates: insights from a study in Ardabil hospitals.
Jafari-Ramedani S; Nazari M; Arzanlou M; Peeri-Dogaheh H; Sahebkar A; Khademi F
BMC Microbiol; 2024 May; 24(1):152. PubMed ID: 38702660
[TBL] [Abstract][Full Text] [Related]
7. Adaptive resistance to the "last hope" antibiotics polymyxin B and colistin in Pseudomonas aeruginosa is mediated by the novel two-component regulatory system ParR-ParS.
Fernández L; Gooderham WJ; Bains M; McPhee JB; Wiegand I; Hancock RE
Antimicrob Agents Chemother; 2010 Aug; 54(8):3372-82. PubMed ID: 20547815
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial Activity of Murepavadin Tested against Clinical Isolates of Pseudomonas aeruginosa from the United States, Europe, and China.
Sader HS; Dale GE; Rhomberg PR; Flamm RK
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29686157
[TBL] [Abstract][Full Text] [Related]
9. Resistance and Heteroresistance to Colistin in Pseudomonas aeruginosa Isolates from Wenzhou, China.
Lin J; Xu C; Fang R; Cao J; Zhang X; Zhao Y; Dong G; Sun Y; Zhou T
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31383654
[TBL] [Abstract][Full Text] [Related]
10. The MerR-like regulator BrlR impairs Pseudomonas aeruginosa biofilm tolerance to colistin by repressing PhoPQ.
Chambers JR; Sauer K
J Bacteriol; 2013 Oct; 195(20):4678-88. PubMed ID: 23935054
[TBL] [Abstract][Full Text] [Related]
11. Mutations and expression of PmrAB and PhoPQ related with colistin resistance in Pseudomonas aeruginosa clinical isolates.
Lee JY; Ko KS
Diagn Microbiol Infect Dis; 2014 Mar; 78(3):271-6. PubMed ID: 24412662
[TBL] [Abstract][Full Text] [Related]
12. Preservation of Acquired Colistin Resistance in Gram-Negative Bacteria.
Lee JY; Choi MJ; Choi HJ; Ko KS
Antimicrob Agents Chemother; 2016 Jan; 60(1):609-12. PubMed ID: 26459897
[TBL] [Abstract][Full Text] [Related]
13. Murepavadin activity tested against contemporary (2016-17) clinical isolates of XDR Pseudomonas aeruginosa.
Sader HS; Flamm RK; Dale GE; Rhomberg PR; Castanheira M
J Antimicrob Chemother; 2018 Sep; 73(9):2400-2404. PubMed ID: 29901750
[TBL] [Abstract][Full Text] [Related]
14. Impact of two-component regulatory systems PhoP-PhoQ and PmrA-PmrB on colistin pharmacodynamics in Pseudomonas aeruginosa.
Ly NS; Yang J; Bulitta JB; Tsuji BT
Antimicrob Agents Chemother; 2012 Jun; 56(6):3453-6. PubMed ID: 22470116
[TBL] [Abstract][Full Text] [Related]
15. PhoQ mutations promote lipid A modification and polymyxin resistance of Pseudomonas aeruginosa found in colistin-treated cystic fibrosis patients.
Miller AK; Brannon MK; Stevens L; Johansen HK; Selgrade SE; Miller SI; Høiby N; Moskowitz SM
Antimicrob Agents Chemother; 2011 Dec; 55(12):5761-9. PubMed ID: 21968359
[TBL] [Abstract][Full Text] [Related]
16. Mutations in genes
Ghassani A; Triponney P; Bour M; Plésiat P; Jeannot K;
Antimicrob Agents Chemother; 2024 Jan; 68(1):e0129823. PubMed ID: 38092672
[TBL] [Abstract][Full Text] [Related]
17. Localized pmrB hypermutation drives the evolution of colistin heteroresistance.
Kapel N; Caballero JD; MacLean RC
Cell Rep; 2022 Jun; 39(10):110929. PubMed ID: 35675785
[TBL] [Abstract][Full Text] [Related]
18. Adaptive and Mutational Responses to Peptide Dendrimer Antimicrobials in Pseudomonas aeruginosa.
Ben Jeddou F; Falconnet L; Luscher A; Siriwardena T; Reymond JL; van Delden C; Köhler T
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015046
[TBL] [Abstract][Full Text] [Related]
19. Rapid and Consistent Evolution of Colistin Resistance in Extensively Drug-Resistant Pseudomonas aeruginosa during Morbidostat Culture.
Dößelmann B; Willmann M; Steglich M; Bunk B; Nübel U; Peter S; Neher RA
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630206
[TBL] [Abstract][Full Text] [Related]
20. Chromosomally Encoded
Snesrud E; Maybank R; Kwak YI; Jones AR; Hinkle MK; McGann P
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29844041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
